Walmart plans to cover GLP-1s and other prescriptions at no cost for employees, according to a reported memo

Walmart is preparing to expand employee health benefits by covering more than 250 prescription medications at no cost to workers, according to a report that cites a staff memo from the company’s Chief People Officer, Donna Morris. The package, as described in the report, would include widely used diabetes treatments such as insulin and popular weight-loss and diabetes drugs in the GLP-1 class, if and when the changes roll out for eligible employees.

The reported effort reflects a broader shift in how large employers are responding to rising drug spending and pricing scrutiny. GLP-1s, or glucagon-like peptide-1 receptor agonists, are prescription medicines used for certain types of diabetes and, for some patients, weight management. The drugs have become a central focus of U.S. pharmacy and employer benefit discussions as demand increased and costs rose faster than many household budgets.

In the memo described by Bloomberg and relayed by Yahoo Finance, Walmart is said to be moving toward a “no cost” prescription approach for a wide list of medications. The report characterizes the plan as covering more than 250 prescriptions at no cost, a breadth that would matter not only for high-profile diabetes and weight-loss therapies but also for a large set of chronic and specialty conditions that rely on ongoing medication.

Walmart’s potential move sits at the intersection of retail labor strategy and health plan economics. For companies with large workforces, health benefits can be a major component of total compensation, affecting recruitment and retention. Covering costly drug categories at $0 can also reduce friction for workers who might otherwise delay filling prescriptions or switch to lower-priced alternatives, outcomes employers may consider both a health and productivity issue.

The report does not lay out the expected start date, the employee eligibility rules, or whether the $0 coverage would apply to all plan designs across Walmart’s footprint. It also does not clarify whether the company would limit coverage to specific GLP-1 products, whether there are step-therapy requirements, or how the benefit interacts with pharmacy networks and existing insurance cost-sharing terms.

A key element of the story is scale. Covering “more than 250” prescriptions suggests a broad rewrite of employee copay structures, rather than a narrow add-on limited to a handful of drugs. Even without specific product names beyond GLP-1s and insulin, expanding a no-cost formulary can be operationally complex, often involving pharmacy benefit managers, plan administration, and contract terms that affect drug prices and rebates.

For workers, the practical significance is straightforward: reducing out-of-pocket costs for medicines that can be expensive, particularly insulin and GLP-1 therapies, which can carry high list prices. For employers, expanding no-cost access may shift costs from employees to the benefits plan, potentially increasing plan spending but also addressing employee financial strain and the reputational risk of workers facing barriers to essential care.

What remains uncertain is how Walmart will define the benefit’s scope and guardrails. The reported memo does not specify whether the company will publish a list of covered medications in advance, what proportion of employees would be included, or what conditions would trigger physician authorization or other utilization controls. The company has not, in the material cited by the report, provided additional details beyond the concept of expanded no-cost coverage.